Darmstadt, Germany, April 3, 2017 — Merck, a leading science and technology company, today announced the launch of its newest high-sensitivity detection platform, SMCxPRO™ technology, at the American Association for Cancer Research Annual Meeting in Washington, D.C.
The SMCxPRO™ platform allows researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design. It will be available in Q3 of 2017.
“Merck’s newest innovation, SMCxPRO™ technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity,” said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation at the life science business sector of Merck. “Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare.”
Along with the new SMCxPRO™ technology, Merck offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company’s suite of gene editing tools.
AACR attendees are encouraged to visit booth #931 to learn more about Merck’s life science products and to speak with company experts. Follow us on twitter @Merck_lifesci.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.